Chemomab Therapeutics Files 6-K for Shareholder Meeting
Ticker: CMMB · Form: 6-K · Filed: May 27, 2025 · CIK: 1534248
| Field | Detail |
|---|---|
| Company | Chemomab Therapeutics LTD. (CMMB) |
| Form Type | 6-K |
| Filed Date | May 27, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-meeting, proxy-statement, corporate-governance
TL;DR
Chemomab (CMMB) filed a 6-K for its shareholder meeting. Details inside.
AI Summary
Chemomab Therapeutics Ltd. filed a Form 6-K on May 27, 2025, to furnish a Notice and Proxy Statement for its upcoming annual general meeting of shareholders. The company, formerly known as Anchiano Therapeutics Ltd. and BioCancell Ltd., is incorporated in Israel and operates in the pharmaceutical preparations sector.
Why It Matters
This filing provides shareholders with essential information regarding the upcoming annual general meeting, including voting procedures and company matters to be discussed.
Risk Assessment
Risk Level: low — This is a routine filing providing notice of an upcoming shareholder meeting and does not contain new financial or operational information that would significantly alter risk.
Key Players & Entities
- Chemomab Therapeutics Ltd. (company) — Filer of the 6-K
- Anchiano Therapeutics Ltd. (company) — Former company name
- BioCancell Ltd. (company) — Former company name
- May 2025 (date) — Reporting period for the 6-K
- 20250527 (date) — Filing date
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K is to furnish a Notice and Proxy Statement with respect to the Company's annual general meeting of the shareholders.
When was Chemomab Therapeutics Ltd. formerly known as Anchiano Therapeutics Ltd. and BioCancell Ltd.?
Chemomab Therapeutics Ltd. was formerly known as Anchiano Therapeutics Ltd. after changing its name on September 6, 2018, and was formerly known as BioCancell Ltd. after changing its name on November 4, 2011.
What is the principal executive office address of Chemomab Therapeutics Ltd.?
The principal executive office address of Chemomab Therapeutics Ltd. is Kiryat Atidim, Building 7, Tel-Aviv, Israel.
Does Chemomab Therapeutics Ltd. file annual reports under Form 20-F or Form 40-F?
Chemomab Therapeutics Ltd. files annual reports under cover of Form 20-F.
What is the SIC code for Chemomab Therapeutics Ltd.?
The Standard Industrial Classification (SIC) code for Chemomab Therapeutics Ltd. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 27, 2025 regarding Chemomab Therapeutics Ltd. (CMMB).